BCL-X L is a key anti-apoptotic BCL-2 family protein that is widely expressed in human cancer cells and is induced in response to diverse survival signals. The translation initiation codon for BCL-X L is located in BCL-X exon II and previous analyses have indicated that BCL-X L RNAs initiate close to the start of exon II or additionally contain a non-coding ®rst exon (exon IA) spliced to exon II. Using 5' RACE we have now identi®ed a novel BCL-X non-coding exon (exon IB) which is spliced directly to exon II in place of exon IA. Exon IB-containing RNAs encoded BCL-X L and were detected in non-malignant lymphocytes and lymphoma cells from lymph node biopsies and were expressed at signi®cant levels in cell lines derived from ovarian, colon and breast cancers. We identi®ed two TATA-box sequences upstream of exon IB and demonstrated that surrounding genomic sequences contained strong promoter activity in lymphoma cells (approximately 300-fold active relative to controls). We have therefore identi®ed a powerful new BCL-X promoter and a novel exon that contributes to BCL-X L expression. Oncogene (2000) 19, 5534 ± 5538.
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Keywords: apoptosis; BCL-X L ; splicing; promoter; transcription BCL-X L is one of the most intensely studied members of the BCL-2 family and is a key regulator of cell survival. BCL-X L shares a high degree of sequence homology with BCL-2 and, like BCL-2, localizes to intracellular membranes and suppresses apoptosis (Boise et al., 1993; Fang et al., 1994; Gonzalez-Garcia et al., 1994; Gotteshalk et al., 1994; Datta et al., 1995; Grillot et al., 1995; Minn et al., 1995 , Schott et al., 1995 Packham et al., 1998) . BCL-X L is widely expressed in cancer cells, including breast, ovarian and colon cancers and lymphoid malignancies Xerri et al., 1996; Olopade et al., 1997; Lohmann et al., 2000) , and overexpression of BCL-X L can promote tumour formation in mouse model systems (Naik et al., 1996; Pena et al., 1998) . BCL-X L expression is also induced by a wide range of survival signals, including cytokines, CD40, EGF or adhesion in various cell types (e.g., Choi et al., 1995; Rodeck et al., 1997; Packham et al., 1998) . Understanding the mechanisms that control BCL-X L expression may provide opportunities to interfere with its function as a means to induce tumour cell apoptosis.
Analysis of BCL-X gene structure and RNA expression identi®ed a three-exon structure (Grillot et al., 1997; see Figure 1a ). The translation initiation and translation termination codons of BCL-X L are located within exons II and III, respectively. Exon I is noncoding and the BCL-X L coding sequence is generated by a splicing event linking exons II and III. Primer extension analysis suggested two clusters of transcription initiation sites, at or close to the start of exon I or close to the start of exon II and a major promoter region was mapped functionally in human K562 erythroid and murine FL5.12 myeloid progenitor cells by deletion analysis to a 57 bp region surrounding the start of exon II.
We performed 5' RACE to characterize the 5' structure of BCL-X RNAs in human lymphoma cells.
Comparison of the sequence of cloned PCR products with human BCL-X genomic sequence revealed several distinct RNA splice structures (Figure 1b) . Three of the clones (B, C and E) were derived from splicing events joining exons I and II, as described (Grillot et al., 1997) . Clone G also linked exons I and II, but was derived from an alternate splicing event using a novel exon II splice acceptor situated 18 nucleotides upstream of the originally identi®ed acceptor. Clone D was contiguous with the genomic sequence and therefore represents an unspliced RNA. Of particular interest, clone F contained a novel exon sequence spliced to exon II in place of exon I. We will refer to this novel upstream exon as exon IB and to the original exon I described by Grillot et al., (1997) as exon IA.
We identi®ed signi®cant homology between the novel exon IB and an EST derived from a human NbHFB cDNA library (EST AA488236, see Figure 1b ). Consistent with our RACE analysis, this EST contained sequences homologous to exon IB at its 5' end and BCL-X L coding sequences at its 3' end. The EST sequence was also derived from a splicing event utilizing the standard exon II splice acceptor but used a dierent exon IB splice donor located 128 nucleotides 3' to that identi®ed in clone F (Figure 1c) . We also identi®ed a high degree of homology with mouse BCL-X genomic sequences indicating that exon IB sequences are well conserved. For example, clone F exon IB sequences are approximately 85% identical to the homologous mouse sequence (Figure 1c ). We performed RT ± PCR using an exon IB primer and a primer annealing within exon III and cDNA derived from HUT78 T-cells (Figure 2a ) or primary non-malignant lymphocytes or lymphoma cells ( Figure  2b ). Two major bands of approximately 800 and/or 900 bp were detected in all cases except a Burkitt lymphoma. We cloned and sequenced the major RT ± PCR products obtained using cDNA prepared from HUT78 cells. Sequencing demonstrated that the cDNAs were derived from splices joining exons IB and II, and II and III and encoded BCL-X L , the major BCL-X isoform in cells. The size dierence between the clones was due to usage of the alternate splice donor at the end of exon IB (Figure 1c) . Interestingly, both clones were derived from the alternate upstream exon II splice acceptor (as identi®ed in RACE clone G, Figure 1 ).
We next analysed expression of RNAs containing the two variant exons using RNase protection assays (RPA) and RNA prepared from cell lines derived from ovarian, colon and breast carcinomas (Figure 3) . In this analysis, full length protection corresponds to the presence of a particular RNA splice structure. Since the exon II content of each probe is the same, the hybridization to this sequence (approximately 140 bp) illustrates the total BCL-X RNA content in each cell line. We readily detected expression of exon IB/II (probe F) and exon IA/II (probe B) spliced RNAs in these cells. Similar results were obtained when RNAs from lymphoid cell lines were analysed (data not shown).
Sequence analysis of a large cosmid clone derived from chromosome 20 which contained the BCL-X gene (GenBank accession number AL160175) showed that the 3' end of exon IB is approximately 1500 base pairs upstream of the BCL-X L ATG (see Figure 1a) . Sequences upstream of exon IB contained two potential TATA box sequences and we therefore determined whether genomic sequences surrounding the 5' end of exon IB were associated with signi®cant promoter activity. We used PCR to amplify a 683 bp genomic fragment containing sequences upstream of exon IB and the 5' part of exon IB (nucleotides 19366 ± 18684) and cloned this region in to a luciferase-based reporter plasmid. Constructs were electroporated into DG75 Burkitt lymphoma cells since these are relatively easy to transfect and express exon IB-containing RNAs (data not shown). The BCL-X genomic region possessed strong promoter activity in DG75 cells and was 200 ± 600-fold more active than the empty control reporter plasmid (Figure 4) . Consistent with containing promoter sequences, the activity of this genomic fragment was largely orientation dependent since 85% of the activity was lost when the same fragment was cloned in the reverse orientation. To begin to determine the sequence elements required for optimal activity of the promoter, we constructed an additional reporter construct lacking sequences at the 3' end of the active 683 bp genomic fragment (pXPB-444F). This construct lacks the downstream TATA box, and its activity was signi®cantly reduced relative to pXPB-683F (Figure 4) .
Our analysis of BCL-X transcription in human cells has uncovered a powerful new BCL-X promoter and a novel upstream non-coding exon that contributes to expression of BCL-X L in a wide range of cell types. We also identi®ed variation in the precise splice donor and acceptor sites used for exon IB and exon II. Although previous studies of dierential splicing have focused on The position of full length protection is indicated by an arrow, and the position of migration of molecular weight markers is shown on the left. Hybridization to a GAPDH probe was also performed to demonstrate that approximately equal amounts of intact RNA were used in each assay mechanisms which lead to the synthesis of multiple BCL-X isoforms, such as BCL-X S , our results demonstrate that a similar level of complexity governs the structure of the 5' non-coding portion of BCL-X RNAs. All splice sites conformed to standard recognition sites and since poly(A) + selected RNA was used to generate cDNA for RACE these mRNAs are mature. Although the variation does not alter the coding potential of BCL-X mRNAs, it may have major signi®cance for the expression and activity of BCL-X L . It is possible that the variant sequences in¯uence the level of BCL-X L expression directly by eects on RNA translation, stability, transport etc. For example, BCL-2 translation is inhibited by an 11 amino-acid upstream open reading frame (Harigai et al., 1996) and it is perhaps signi®cant that there are two conserved ATGs in exon IB. The high degree of sequence homology between mouse and human, despite lack of coding potential, supports the idea that these sequences play a role in controlling BCL-X L expression.
There appear therefore to be at least three promoters which are used to drive expression of BCL-X RNAs. Grillot et al. (1997) identi®ed a 57 bp region close to the 5' end of exon II in the mouse gene that contained signi®cant promoter activity and a second promoter used to drive expression of exon IA RNAs was inferred from the structures of cDNAs. Our analysis now demonstrates that a further promoter contributes to BCL-X L expression in human cells resulting in the expression of a novel non-coding exon IB in place of exon IA. The high degree of sequence homology between exon IB and mouse BCL-X sequences strongly suggests that similar transcripts occur in the mouse. Although we identi®ed only RNAs initiating at exon IA or IB in our RACE analysis, it should be noted that RNAs initiating near to exon II would have been too small to clone and similar to mouse cells, additional human BCL-X RNAs may initiate at or near the start of exon II.
The new promoter region contains putative binding sites for several transcription factors, including Ikaros and c-Ets family proteins, and a direct repeat element which comprises multiple overlapping sequences which are a single base dierent from an optimal AP-1 binding site. The region also contains two potential TATA boxes and at present we do not know whether both are important. A construct lacking the downstream TATA box was signi®cantly less active than the larger promoter fragment perhaps suggesting that the upstream TATA-box is most important for the activity of this promoter. Alternatively, it is possible that this decrease in activity was due to deletion of important transcription factor binding sites within this region. Future experiments will identify the precise sequence elements required for the activity of this promoter in dierent cell types.
We readily detected expression of both IA/II and IB/ II spliced RNAs in a wide range of cell lines. There was also some evidence for dierential regulation, since there were dierences in the relative abundance in certain cell lines. For example, in MCF7 breast cancerderived cells, exon IB/II RNAs were relatively highly expressed, whereas exon IA/II RNAs were expressed at a relatively low level. Conversely, RKO colon cancer cells expressed relatively low levels of exon IB/II RNAs, but relatively high levels of exon IA/II RNAs. The amount of full length protection appears to be modest for each probe suggesting that these speci®c RNAs make a relatively minor contribution to total BCL-X mRNA. However, it is important to recognize that full length protection only re¯ects those RNAs which exactly match the probe. Therefore, given the variability in the precise splice site linking, for example exon IB and II, this approach will underestimate that total amount of RNAs containing exon IB.
BCL-X L is widely expressed in cancer cells and is induced by a wide range of survival signals. It will be interesting to determine whether distinct promoters and/or sequence elements mediate responses to the diverse range of survival signals that induce BCL-X L expression and if the alternate BCL-X promoters are dierentially used in normal and malignant cells. Figure 4 A novel Bcl-X promoter active in lymphoid cells. A 683 bp fragment of the BCL-X gene surrounding the start of exon IB was ampli®ed using primers F23181 (GGGCGGCCTCAGTT-TCCCCTGA) and F23180 (GGGCGCCTGTAAACGATC-TCCC) and cloned in forward and reverse orientation into pGL2-Basic (Promega) to give pXPB-683F and pXPB-683R, respectively. A 444 bp fragment, lacking 3' sequences, was also cloned using primers F23180 and F23179 (GGGGTCAAT-CAGCCTATTCATCCG) to give pXPB-444F. The constructs (20 mg) were transfected into DG75 cells by electroporation (parameters of 900 mF and 250 mV). As a control for transfection eciency, all transfections additionally contained 2 mg of CMV bgal plasmid. Cells were collected 24 h after transfection and luciferase and b-galactosidase assays performed. Results are representative of three separate experiments and are mean of duplicate transfections. Some errors are too small to show
